In HIV-infected patients with abdominal fat treated with tesamorelin, those with at least 8% VAT reduction had a greater fall in triglycerides than nonresponders.
In plain wordsOn tesamorelin, HIV-infected patients whose belly fat fell 8% or more had a bigger triglyceride drop than those whose belly fat fell less.
- Peptide
- Tesamorelin
- Outcome
- DecreaseTriglyceride change in VAT responders vs nonresponders
- Study
n = 402
- Comparator
- Tesamorelin nonresponders
- Outcome group
- Lipids · Metabolic and weight
- Studied dose
- Dose not stated · 26 to 52 weeksAs given in this study (human).
Measurements
- Triglyceride change at 26 weeks
- −0.6 mmol/L
- responders
- Triglyceride change at 26 weeks
- −0.1 mmol/L
- nonresponders
- Triglyceride change at 52 weeks
- −0.8 mmol/L
- responders
Source sentences
Compared with tesamorelin nonresponders, responders experienced greater mean (±SD) reduction in triglyceride levels (26 weeks: -0.6 ± 1.7 mmol/L vs -0.1 ± 1.2 mmol/L [P = .005]; 52 weeks: -0.8 ± 1.8 mmol/L vs 0.0 ± 1.1 mmol/L [P = .003]
2 context sentences(design, population, supporting numbers)
In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdominal fat accumulation were randomly assigned (ratio, 2:1) to receive tesamorelin or placebo for 26 weeks.
In per-protocol analysis of 402 subjects initially randomly assigned to receive tesamorelin, those with ≥8% reduction in VAT were defined a priori as responders per the statistical analysis plan.